A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gotham Asset Management, LLC holds 24,711 shares of VRTX stock, worth $12.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
24,711
Previous 18,318 34.9%
Holding current value
$12.4 Million
Previous $7.66 Million 51.26%
% of portfolio
0.15%
Previous 0.12%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $2.51 Million - $3.1 Million
6,393 Added 34.9%
24,711 $11.6 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $499,420 - $546,448
1,225 Added 7.17%
18,318 $7.66 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $1.71 Million - $2.05 Million
4,992 Added 41.25%
17,093 $6.95 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $219,140 - $234,874
648 Added 5.66%
12,101 $4.21 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $164,127 - $183,697
-522 Reduced 4.36%
11,453 $4.03 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $3.9 Million - $4.45 Million
-13,765 Reduced 53.48%
11,975 $3.77 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $3.39 Million - $3.82 Million
-11,867 Reduced 31.56%
25,740 $7.43 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $2.41 Million - $2.69 Million
8,791 Added 30.51%
37,607 $10.9 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $313,906 - $390,846
1,336 Added 4.86%
28,816 $8.12 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $1.05 Million - $1.23 Million
4,725 Added 20.76%
27,480 $7.17 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $440,400 - $555,943
2,488 Added 12.28%
22,755 $5 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $2.91 Million - $3.26 Million
-16,038 Reduced 44.18%
20,267 $3.68 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $6.81 Million - $8.03 Million
36,305 New
36,305 $7.32 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $316,104 - $421,589
-1,527 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $2,045 - $2,424
-8 Reduced 0.52%
1,527 $416,000
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $100,789 - $132,222
-447 Reduced 22.55%
1,535 $446,000
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $168,805 - $209,399
845 Added 74.32%
1,982 $472,000
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $10 Million - $13.5 Million
-60,130 Reduced 98.14%
1,137 $249,000
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $9.89 Million - $11.1 Million
59,466 Added 3301.83%
61,267 $10.4 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $296,462 - $342,856
1,801 New
1,801 $330,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $2.18 Million - $2.54 Million
-14,974 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $1,516 - $1,771
-10 Reduced 0.07%
14,974 $2.44 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $13.1 Million - $14.9 Million
-95,516 Reduced 86.44%
14,984 $2.25 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $16.4 Million - $17.9 Million
110,500
110,500 $16.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.